19-22 Oktober in Atlanta

Slides und Poster Gilead

HIV PREVENTION
LEN4PrEP
Jesse Clark	Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances
Disebo Potloane	No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1
Jill Blumenthal	No Clinically Significant Drug-Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice-yearly Lenacapavir PrEP in Gender-Diverse Persons
PrEP LANDSCAPE
Xiwen Huang	Real-World Sexually Transmitted Infection (STI) Testing Patterns Among Individuals Using Pre-Exposure Prophylaxis (PrEP) for HIV-1 Prevention in the United States
Richard A. Elion	PrEP Utilization Patterns and Indications in a Cohort of HIV-Negative Individuals
Patrick Sullivan	Barriers to Oral HIV Pre-Exposure Prophylaxis (PrEP) Perceived by Those Receiving an Initial Prescription: US Survey Analysis
Cynthia Firnhaber	Telehealth as a Modality to Improve the Uptake of PrEP Services in Black and Latino MSM "ePrEP"
HIV TREATMENT
B/F/TAF
Sharon Walmsley	A Phase 4 Study to Evaluate the Safety and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV
Samir K. Gupta	Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Cabotegravir + Rilpivirine: Results From the Phase 4 EMPOWER Study
GraemeMoyle	Characteristics and Outcomes of People with HIV (PWH) with Suboptimal Adherence on B/F/TAF or Dolutegravir Single-Tablet Regimens (STRs)
BenjaminChastek	Antiretroviral Therapy Persistence Following a Change or Restart in Regimen Among People with HIV
Suying Li	Treatment Switch among Medicare-insured People with HIV and Gaps in Care
Travis Lim	Persistence and Adherence of People with HIV (PWH) and Mental Health Disorder Diagnosis who Restart Antiretroviral Therapy (ART)
Hilal Abdessamad	Reaching the Hard-to-Reach ACCELERATE Model of HIV Care: Telehealth, Rapid Restart, Follow-up
T’shura Ali	Impact of Rapid Antiretroviral Therapy Initiation on Retention in Care and Viral Suppression in an urban HIV clinic in Louisville, Kentucky
TREATMENT LANDSCAPE
Xavier Guillaume	HIV Viewpoints: Survey on the Experiences of People Living with HIV in Canada, Mexico, and the United States
Dona Khoshabafard	Geographic Variations of HIV Specialist Shortages: An Observational Study to Support the 90-90-90 HIV Treatment Goals in the US
Laura Mitten	Evaluation of Implementing Text-Messaging Based Medication Reminders to Improve Adherence to Antiretrovirals in People Living with HIV
Patrick Ryscavage	Improving Access and Adherence to Antiretroviral Therapy Through Coordinated Outreach and Care Linkage Model: A Collaborative Program Evaluation
LEN for THE
Karam Mounzer	Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort
ISL/LEN
Jing Niu	Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir
LEN+bNAbs
Kimberly Workowski	Pooled Safety and Tolerability of Twice-Yearly Lenacapavir with Teropavimab and Zinlirvimab for HIV-1 Treatment
Nan Zhang	Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab

19-22 Oktober in Atlanta

Slides und Poster Gilead

Meldungen

Pneumokokken

Langwirksame ART

Mikrobiom

Epstein-Barr-Virus

Newsletter Infection&more online

Clostridium difficile

HIV

Atemwegsinfekt

Antimikrobielle Resistenz

STI

Antihelmintika

HIV

Robert Koch-Institut

Antiretrovirale Therapie

Epstein-Barr-Virus

MPOX

Ältere Meldungen